Summary

In part 2 of the phase 3 ANNEXA-A trial, older subjects receiving a steady dose of apixaban were randomized to receive a bolus plus an infusion of andexanet alfa or placebo in a 3:1 ratio. Andexanet significantly reduced anti-fXa activity, decreased free apixaban, and normalized anticoagulation parameters. It was well tolerated in all study participants.